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Summary
Background Active management of the third stage of labour reduces the risk of post-partum haemorrhage. We aimed 
to assess whether controlled cord traction can be omitted from active management of this stage without increasing 
the risk of severe haemorrhage. 
Methods We did a multicentre, non-inferiority, randomised controlled trial in 16 hospitals and two primary health-
care centres in Argentina, Egypt, India, Kenya, the Philippines, South Africa, Thailand, and Uganda. Women expecting 
to deliver singleton babies vaginally (ie, not planned caesarean section) were randomly assigned (in a 1:1 ratio) with a 
centrally generated allocation sequence, stratiﬁ ed by country, to placental delivery with gravity and maternal eﬀ ort 
(simpliﬁ ed package) or controlled cord traction applied immediately after uterine contraction and cord clamping (full 
package). After randomisation, allocation could not be concealed from investigators, participants, or assessors. 
Oxytocin 10 IU was administered immediately after birth with cord clamping after 1–3 min. Uterine massage was 
done after placental delivery according to local policy. The primary (non-inferiority) outcome was blood loss of 1000 mL 
or more (severe haemorrhage). The non-inferiority margin for the risk ratio was 1·3. Analysis was by modiﬁ ed 
intention-to-treat, excluding women who had emergency caesarean sections. This trial is registered with the Australian 
and New Zealand Clinical Trials Registry, ACTRN 12608000434392.
Findings Between June 1, 2009, and Oct 30, 2010, 12 227 women were randomly assigned to the simpliﬁ ed package 
group and 12 163 to the full package group. After exclusion of women who had emergency caesarean sections, 
11 861 were in the simpliﬁ ed package group and 11 820 were in the full package group. The primary outcome of blood 
loss of 1000 mL or more had a risk ratio of 1·09 (95% CI 0·91–1·31) and the upper 95% CI limit crossed the pre-stated 
non-inferiority margin. One case of uterine inversion occurred in the full package group. Other adverse events were 
haemorrhage-related.
Interpretation Although the hypothesis of non-inferiority was not met, omission of controlled cord traction has very 
little eﬀ ect on the risk of severe haemorrhage. Scaling up of haemorrhage prevention programmes for non-hospital 
settings can safely focus on use of oxytocin.
Funding United States Agency for International Development and UN Development Programme/UN Population 
Fund/WHO/World Bank Special Programme of Research, Development and Research Training in Human 
Reproduction, Department of Reproductive Health and Research. 
Introduction
Post-partum haemorrhage is a major cause of severe 
morbidity and maternal death, particularly in Africa and 
Asia, where nearly a third of pregnancy-related deaths are 
associated with haemorrhage.1 Most such deaths occur 
because of insuﬃ  cient uterine contraction soon after 
birth. Two management packages for the third stage of 
labour are commonly used, known as active manage ment 
and expectant management.2 In active management, 
several prophylactic interventions are applied in combin-
ation. WHO recommends administration of oxytocin 
soon after delivery of the baby, controlled cord traction, 
and delayed clamping and cutting of the cord until the 
health-care worker is ready to apply traction.3 Uterine 
massage after placental delivery is included in professional 
society guidelines.4 In expectant management,  the inter-
ventions included in active management are withheld 
unless needed. Randomised trials5,6 of active versus expec-
tant management have been done in hospital settings and 
they included early clamping and cutting of the cord in 
addition to the WHO components. Overall, the risk of 
post-partum haemorrhage was more than 60% lower 
with active management than with expectant manage-
ment. The timing of cord clamping does not seem to play 
a signiﬁ cant part in blood loss.7 Side-eﬀ ects such as 
increased blood pressure, nausea, vomiting, and increased 
placental retention are generally attributed to the use of 
uterotonic ergot alkaloids. 
WHO recommendations published in 20073 advo-
cated use of the full active management package, while 
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acknowledging the absence of evidence for the eﬀ ective-
ness of some individual components. Estimation of the 
relative contribution of each of the components could 
help to determine the most eﬀ ective way to use the 
intervention at diﬀ erent levels of health care or by health-
care workers with diﬀ erent skills.6 Some evidence sug-
gests that the uterotonic component can be eﬀ ective on 
its own.8,9 However, the contribution of controlled cord 
traction is largely unknown. 
In controlled cord traction10 the birth attendant pushes 
the uterine fundus upwards with one hand while the 
other hand applies continuous traction on the umbilical 
cord to extract the placenta.11 Because the procedure 
requires manual skills, it has been recommended for 
use by skilled birth attendants only. However, if traction 
does not have a meaningful eﬀ ect on blood loss then it 
could be omitted and a simpliﬁ ed package focusing 
mainly on the uterotonic could be recommended. Such a 
recom mendation would have important implications for 
reducing resources required to train and deploy health-
care personnel attending childbirth and could expand 
access to eﬀ ective care in places where staﬀ  shortages and 
physical barriers to access remain.
We aimed to ﬁ nd out whether a simpliﬁ ed approach to 
management of the third stage of labour without 
controlled cord traction is not less eﬀ ective than the full 
active management package at reduction of severe blood 
loss (ie, ≥1000 mL). 
Methods
Study design and patients
We did a multicentre, non-inferiority, randomised 
controlled trial in 16 hospitals and two primary health-
care centres in Argentina, Egypt, India, Kenya, the 
Philippines, South Africa, Thailand, and Uganda. Before 
the trial started we assessed the existing policies at the 
study sites. With the exception of the two primary-care 
centres in India, all sites practised controlled cord traction. 
All sites used intramuscular or intravenous oxytocin 
10 IU, although the timing of administration diﬀ ered. In 
the Philippines, a policy of concurrent use of intramuscular 
oxytocin and ergometrine was in place before the trial. In 
Argentina and Kenya, cord clamping was described as 
delayed, whereas other sites were practising immediate 
cord clamping. Uterine massage after placental delivery 
was part of routine management in the Philippines and 
Thailand and reported as about 50% in Egypt. It was not 
part of routine policy in any of the other countries.
All women expecting to deliver vaginally at the 
participating hospitals were potentially eligible. They 
were excluded if they were ﬁ rst seen in advanced labour 
(>6 cm cervical dilatation), were not capable of giving 
consent because of an obstetric emergency, a mental 
disorder, or distress, or if they planned to have caesarean 
section, were minors without a guardian, or had twin 
pregnancies. The fetus had to be at a gestational age of 
viability according to local limits. Women were asked for 
written informed consent either before or early in labour. 
The trial protocol was approved by the WHO Ethics 
Review Committee and the local ethics committees of the 
participating institutions.
Randomisation and masking
Random allocation took place as close to the anticipated 
vaginal delivery as possible. The random allocation 
sequence was computer generated centrally at WHO. 
Randomisation was stratiﬁ ed by country and restricted 
with randomly varying blocks of six to eight. At each 
facility, a computer programmed with the random allo-
cation sequence was provided and allocation was made 
once the woman’s details were entered into the computer 
by local investigators. Each site had one spare computer in 
case of break-down or theft; if both failed the centre had to 
revert to sealed opaque envelopes as the back-up option. 
Centres in Egypt and Kenya had to revert to sealed opaque 
envelopes because of break-down and theft midway 
through the trial. Neither the investigators nor participants 
could be masked to the interventions or outcomes.
Procedures
In both groups of the trial, intramuscular oxytocin 10 IU 
was administered as soon as possible after birth, 
preferably within 1 min. If a woman had an intravenous 
line, oxytocin diluted in 100 mL saline could be 
administered through the line for 5 min. The cord was 
clamped and cut after manual or visual observation of a 
uterine contraction, usually around 1–3 min after delivery 
of the baby. Collection of lost blood was initiated 
immediately after birth of the baby by passing a drape 
under the woman’s buttocks.12 Blood collected in the 
drape was put in a bucket, weighed on a digital scale 
together with the drape, and the amount recorded in 
grams. Trial interventions were administered by the staﬀ  
who managed the deliveries. For the analysis, the weight 
of the drape was subtracted and the weights were 
converted to volumes; the value in grams was divided by 
1·06 (blood density in g/mL).13  
The experimental intervention assessed in the trial 
was the simpliﬁ ed package, in which placental delivery 
was allowed to occur with the aid of gravity and maternal 
eﬀ ort. The birth attendant was expected to note the signs 
of placental separation such as a gush of blood, uterine 
contraction, lengthening of the umbilical cord, and 
visualisation of the placenta in the vagina, and then 
encourage the woman to cough or push. The control was 
the full package, in which controlled cord traction was 
applied immediately after observation of a uterine 
contraction. The cord was clamped and cut as described 
for the simpliﬁ ed package. The full package practised in 
the trial was applied as in other active management trials 
except for timing of cord clamping. However, available 
evidence suggests that the timing of cord clamping is 
not likely to have a major eﬀ ect on blood loss.7 The 
protocol required that after placental delivery the uterine 
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fundus was rubbed and any clots expressed. Because 
policies for uterine massage varied and no evidence to 
support or refute its role is available, individual sites 
were allowed to implement it or not according to their 
existing routine. The protocol stated that, if the procedure 
was used, the uterus should be massaged gently until it 
contracted and then every 15 min for up to 2 h. Adherence 
to allocated treatment was deﬁ ned as hands-oﬀ  manage-
ment of the cord in the simpliﬁ ed package group and 
application of cord traction within 30 min of delivery in 
the full package group.
The primary (non-inferiority) outcome was severe post-
partum haemorrhage deﬁ ned as measured blood loss of 
1000 mL or more at 1 h and up to 2 h for women who 
continued to bleed after 1 h. The secondary (superiority) 
outcomes were blood transfusion, use of additional utero-
tonics, blood loss of 500 mL or more, maternal death, 
manual placental removal, surgical procedures (hyster-
ectomy, ligation of vessels), the composite outcome of 
maternal death or severe morbidity (admission to intensive-
care unit, hysterectomy, blood loss of 2000 mL or more, 
uterine inversion), and initiation of breastfeeding. 
The Data Safety and Monitoring Committee met three 
times during the course of the project. The Committee 
reviewed two interim analyses according to the Haybittle-
Peto rule14 with a superiority criterion on the primary 
outcome. The committee advised the trial Steering 
Committee to continue recruitment on both occasions.
Statistical analysis
We aimed to assess non-inferiority of the simpliﬁ ed 
package compared with the full package in terms of 
eﬃ  cacy within a pre-stated non-inferiority margin. We 
chose the non-inferiority margin by examining the eﬀ ect 
of the gold standard, in this case full active management, 
compared with expectant management (control) in 
previous trials.5,15 Estimates of severe post-partum 
haemorrhage with active and expectant management 
were taken from published and unpublished data of 
WHO studies in which post-partum blood loss was 
measured.5,9,16 On the basis of those data, we assumed a 
1·5% risk of severe haemorrhage with the full package. 
The severe haemorrhage rate with expectant management 
was based on data available from earlier trials.5,15 Values 
between 3·0% and 4·0% were judged realistic. For 
sample size estimates, we therefore assumed a 3% risk 
of severe haemorrhage with expectant management. The 
simpliﬁ ed package was assumed to preserve 70% of the 
beneﬁ t of the full active management package. With 
these assumptions, a trial of 22 908 women would have 
80% power to show non-inferiority of the simpliﬁ ed 
package within 0·45% of the severe haemorrhage rate 
for the full package (ie, [1·0–0·7] × [3·0–1·5], with a 
two-sided 95% CI, and an α of 2·5%). In relative 
terms, this gives a margin of non-inferiority of 1·3 
(ie [1·5 + 0·45] / 1·5 = 1·95 / 1·5). The non-inferiority 
hypo thesis was used for the primary outcome. For the 
secondary endpoints superiority hypotheses were used. 
SAS version 9.1 was used for all analyses.
We identiﬁ ed two analysis populations: intention-to-
treat population—all enrolled women assessed within 
groups as randomised, irrespective of adherence—and 
modiﬁ ed intention-to-treat population—as intention-to-
treat population, but excluding women having a caesarean 
section after randomisation. Our primary analysis and 
interpretation are based on the modiﬁ ed intention-to-
treat population. We chose to focus on this population 
because for women having a caesarean section (whether 
elective or emergency), the trial interventions could not 
be implemented, nor the primary outcome assessed, in 
the same way as with a vaginal delivery. Elective caesarean 
section was an exclusion criterion but some emergency 
caesarean sections occurred after randomisation.
Although some researchers have suggested that in 
non-inferiority trials per-protocol analysis provides a 
more conservative interpretation,17 this notion has been 
disputed.18 In this trial, women with much blood loss in 
the simpliﬁ ed group were more likely to receive cord 
traction and other interventions to remove the placenta 
than were women with little blood loss. Because women 
with great blood loss would be excluded in a per-protocol 
analysis, the results would favour the simpliﬁ ed pack-
age group, and push the results towards erroneous 
non-inferiority.
Because the eﬀ ects of uterine massage with or without 
the full package were unknown, we planned stratiﬁ ed 
analysis according to the policy of use or non-use of 
uterine massage. Finally, we did sensitivity analyses with 
and without the data set from the Philippines. We 
Figure: Trial proﬁ le
AMTSL=active management of the third stage of labour. ITT=intention to treat. 
36 131 assessed for eligibility
24 390 randomised
366 caesarean sections 343 caesarean sections
12 227 allocated to the simpliﬁed AMTSL package
11 265 received the allocated intervention
962 did not receive allocated intervention
12 163 allocated to the full AMTSL package
11 547 received the allocated intervention
616 did not receive allocated intervention
11 861 analysed (modiﬁed ITT population)
11 253 received the allocated intervention
608 did not receive allocated intervention
11 820 analysed (modiﬁed ITT population)
11 406 received the allocated intervention
414 did not receive allocated intervention
11 741 excluded
9186 did not meet the inclusion criteria
2544 not eligible after screening before
randomisation
11 other reasons
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decided on the sensitivity analysis after the protocol was 
written but before the analysis. In the Philippines, both 
study sites were large, high-volume hospitals and 
frequent closures occurred because of repairs and 
infections in the neonatal units that led to interruptions 
in recruitment and loss of study forms (140 of 2527 [5·5%] 
in the simpliﬁ ed package group and 137 of 2524 [5·4%] 
in the full package group). When examining the quality 
of data from the Philippines, we noted that in one of the 
two sites, the routine policy of oxytocin and ergometrine 
administration from before initiation of the study 
continued during the trial. For these reasons, and 
especially in view of the association of ergometrine with 
placental retention identiﬁ ed in published work,5 the 
trial steering committee decided that the sensitivity 
analyses were justiﬁ ed. This trial is registered with the 
Australian and New Zealand Clinical Trials Registry, 
ACTRN 12608000434392.
Role of the funding source
The study was supported by the United States Agency for 
International Development and UN Development 
Programme/UN Population Fund/WHO/World Bank 
Special Programme of Research, Development and 
Research Training in Human Reproduction, Department 
of Reproductive Health and Research, WHO. The 
sponsors had no role in data collection, analysis, or 
interpretation of the data, the writing of the report, or the 
decision to submit for publication. All authors had access 
to the analysis plan, the outputs of that analysis and could 
see the data if they wished to do so. All authors participated 
in the ﬁ nal discussion and approved the submission. 
Results
The ﬁ gure shows the trial proﬁ le. Enrolment took place 
between June 1, 2009, and Oct 30, 2010. 3455 women 
were in Argentina, 3527 in Egypt, 2165 in India, 4005 in 
Kenya, 5051 in the Philippines, 1277 in South Africa, 
3181 in Thailand, and 1729 in Uganda. Table 1 shows 
patient characteristics at trial entry and delivery. 
Adherence to the oxytocin and controlled cord traction 
components was high (>90%), with overall package 
adherence reduced mainly because of the timing of cord 
clamping and cutting (table 2). Rates of early cord 
clamping were particularly high in some of the Thai 
facilities because of hospital policies. Most sites did not 
practise uterine massage regularly, except Egypt (2507 of 
3518 cases, 99·7%), Thailand (2790 of 2976, 93·7%), and 
Uganda (1715 of 1723 cases, 99·8%). In all other sites 
uterine massage was used in less than 10% of cases. 
Some diﬀ erences between policies before and at the end 
of the trial are to be expected because the principal 
investigators attempted to bring their policies in line with 
trial procedures. About 6% of all women allocated to the 
simpliﬁ ed package eventually needed controlled cord 
traction (table 2). We were not able to diﬀ erentiate 
whether their placentas were truly retained or whether 
the total included women whose placentas were already 
separated but not expelled by maternal eﬀ orts.
Table 3 shows primary and secondary outcomes. For 
the primary endpoint, the upper range of the 95% CI 
lies slightly above the non-inferiority limit (1·30). The 
risk of the secondary outcome of post-partum haemor-
rhage was higher in women given the simpliﬁ ed package 
than in those given the full package (risk ratio 1·07, 
95% CI 1·00–1·14, superiority hypothesis). The rate of 
manual placental removal was signiﬁ cantly higher in 
the simpliﬁ ed package group (table 3). Mean blood loss 
was about 11 mL greater and the third stage about 7 min 
longer with the simpliﬁ ed package than with the full 
package. One case of uterine inversion occurred in 
the full package group. Other adverse events were 
haemorrhage-related. 
In the sensitivity analysis excluding the Philippines 
(table 4), the summary estimates had slightly larger CIs, 
and the statistically signiﬁ cant diﬀ erence in the rate of 
Simpliﬁ ed package Full package
Age (years)* 25·3 (5·6) 25·3 (5·6)
Primigravidae 5362/11 823 (45%) 5476/11 799 (46%)
Duration of gestation ≥37 weeks 10 713/11 815 (91%) 10 620/11 797 (90%)
Labour induced or augmented 5923/11 815 (50%) 5796/11 795 (49%)
Spontaneous cephalic vaginal delivery 11 266/11 818 (95%) 11 240/11 795 (95%)
Perineal trauma (episiotomy or tear requiring suture) 7667/11 816 (65%) 7616/11 791 (65%)
Birthweight (g)† 3069 (538) 3054 (544)
Baby alive 11 661/11 818 (99%) 11 639/11 797 (99%)
Data are n/N (%) or mean (SD). Denominators vary because of missing data. *N=11 861 for the simpliﬁ ed group, and 
11 820 for the full package group. †N=11 818 for the simpliﬁ ed group, and 11 797 for the full package group.
Table 1: Characteristics of women at trial entry and delivery for the modiﬁ ed intention-to-treat population
Simpliﬁ ed package Full package
Adherence
Cord management according to protocol*† 11 253 (95%) 11 406 (97%)
Oxytocin administered† 11 779 (99%) 11 751 (99%)
Delayed cord clamping and cutting† 9321 (79%) 9242 (78%)
Interventions used for ﬁ nal delivery of the placenta‡
Hands oﬀ  (maternal eﬀ ort)§ 10 668 (91%) 833 (7%)
Controlled cord traction¶ 731 (6%) 11 389 (97%)
Umbilical vein injection|| 10 (<1%) 10 (<1%)
Manual removal || 153 (1%) 105 (<1%)
Curettage|| 165 (1%) 98 (<1%)
Hysterectomy|| 2 (<1%) 6 (<1%)
Left in situ because of severe adherence** 2 (<1%) 6 (<1%)
Placenta and baby delivered simultaneously†† 29 (<1%) 23 (<1%)
Data are n (%). Denominators vary because of missing data. *Hands-oﬀ  in the simpliﬁ ed package and controlled cord 
traction in the ﬁ rst 30 min in the full package. †N=11 861 for the simpliﬁ ed package, and 11 820 for the full package. 
‡More than one intervention could be used for any one patient. §N for hands oﬀ  is 11 776 for the simpliﬁ ed package, 
and 11 763 for the full package. ¶N for controlled cord traction is 11 777 for the simpliﬁ ed package, and 11 766 for the 
full package. ||N for umbilical vein injection, manual removal, curettage, and hysterectomy is 11 814 for the simpliﬁ ed 
package, and 11 794 for the full package. **N for left in situ is 11 813 for the simpliﬁ ed package and 11 792 for the full 
package. ††N for delivered simultaneously is 11 814 for the simpliﬁ ed package, and 11 797 for the full package. 
Table 2: Adherence to trial interventions and ﬁ nal mode of placental delivery
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manual placental removal was no longer apparent. 
Mean blood loss was still greater and the third stage 
longer with the simpliﬁ ed package than with the full 
package. We recorded uterine massage after placental 
delivery and did a pre-speciﬁ ed subgroup analysis of 
the primary and secondary outcomes with or without 
uterine massage (data not shown). The interaction test 
did not suggest that the outcomes diﬀ ered according to 
this policy (p=0·61).
Discussion
Our ﬁ ndings suggest that omission of cord traction 
results in very little, if any, increased risk of severe 
haemorrhage. The primary outcome of blood loss of 
1000 mL or more has a risk ratio of 1·09 (95% CI 0·91 
to 1·31) and the upper 95% CI limit crosses the pre-stated 
non-inferiority margin of 1·30 (appendix). If the upper 
limit had been below 1·30 we would have declared the 
simpliﬁ ed package non-inferior to the full package.19 The 
estimated number needed to harm (the reciprocal of the 
risk diﬀ erence 0·17%) is 581 (one-sided 97·5% CI  189 
to ∞), indicating that for every 581 women receiving the 
simpliﬁ ed package, one additional woman would have a 
severe haemorrhage than if all received the full package. 
We draw two inferences from these results: ﬁ rst, control-
led cord traction is safe and its use can be continued in 
settings in which it is routinely practised; and second, 
the main component of active management is the 
uterotonic and in settings in which the full package 
cannot be used safely, focus should be on the uterotonic 
component (panel).
The higher rate of manual removal with the simpliﬁ ed 
package is probably attributable to the high use of 
ergometrine as prophylaxis in one of the Philippines 
Simpliﬁ ed package Full package % risk diﬀ erence (95% CI) Risk ratio (95% CI)
Blood loss ≥1000 mL* 239 (2%) 219 (2%) 0·17 (–0·19 to 0·53) 1·09 (0·91 to 1·31)
Blood loss ≥500 mL* 1598 (14%) 1493 (13%) 0·90 (0·03 to 1·78) 1·07 (1·00 to 1·14)
Blood loss in mL† 282 271 10·8 (4·7 to 16·9) ··
Additional uterotonics‡ 2434 (21%) 2390 (20%) 0·34 (–0·69 to 1·37) 1·02 (0·97 to 1·07)
Blood transfusion§ 62 (<1%) 55 (<1%) 0·06 (–0·12 to 0·24) 1·12 (0·78 to 1·62)
Manual removal of placenta¶ 153 (1%) 105 (<1%) 0·40 (0·14 to 0·67) 1·45 (1·14 to 1·86)
Third stage duration in min|| 12·6 6·1 6·5 (6·2 to 6·8) ··
Maternal death** 2 (<1%) 1 (<1%) 0·01 (–0·02 to 0·04) 2·00 (0·18 to 22·0)
Additional surgical procedures†† 2 (<1%) 9 (<1%) –0·06 (–0·11 to 0·00) 0·22 (0·05 to 1·03)
Maternal death or severe morbidity‡‡ 20 (<1%) 31 (<1%) –0·09 (–0·22 to 0·03) 0·65 (0·37 to 1·13)
Baby put to breast within 30 min§§ 10 565 (90%) 10 532 (90%) 0·14 (–0·62 to 0·91) 1·00 (0·99 to 1·01)
Data are n (%) or mean (SD) unless otherwise speciﬁ ed. *N=11 621 for both packages. †Denominator is 11 621 for both groups. ‡N= 11 802 for the simpliﬁ ed package, and 
11 783 for the full package. §N=11 814 for the simpliﬁ ed package, and 11 790 for the full package. ¶N=11 814 for the simpliﬁ ed package, and 11 794 for the full package. 
||Denominator is 11 662 for simpliﬁ ed package, and 11 648 for full package. **N=11 818 for the simpliﬁ ed package, and 11 798 for the full package. ††N=11 814 for the 
simpliﬁ ed package, and 11 790 for the full package. ‡‡N=11 616 for both packages. §§N=11 711 for the simpliﬁ ed package, and 11 693 for the full package.
Table 3: Trial outcomes for the modiﬁ ed intention-to-treat population
Simpliﬁ ed package Full package % risk diﬀ erence (95% CI) Risk ratio (95% CI)
Blood loss ≥1000 mL* 153 (2%) 140 (2%) 0·14 (–0·21 to 0·49) 1·09 (0·87 to 1·37)
Blood loss ≥500 mL* 987 (11%) 927 (10%) 0·65 (–0·22 to 1·51) 1·07 (0·98 to 1·16)
Blood loss (mL)† 266 256 10·2 (3·9 to 16·4) ··
Additional uterotonics‡ 1026 (11%) 962 (10%) 0·66 (–0·21 to 1·54) 1·07 (0·98 to 1·16)
Blood transfusion§ 50 (<1%) 34 (<1%) 0·17 (–0·02 to 0·36) 1·47 (0·95 to 2·27)
Manual removal of placenta¶ 62 (<1%) 64 (<1%) –0·02 (–0·25 to 0·21) 0·97 (0·68 to 1·37)
Third stage duration (min)|| 11·4  6·2 5·2 (4·9 to 5·5) ··
Maternal death** 1 (<1%) 1 (<1%) 0·00 (–0·03 to 0·03) 1·00 (0·06 to 16·0)
Additional surgical procedures§ 0 3 (<1%) –0·03 (–0·07 to 0·00) ··
Maternal death or severe morbidity†† 12 (<1%) 15 (<1%) –0·03 (–0·14 to 0·08) 0·80 (0·37 to 1·71)
Baby put to breast within 30 min‡‡ 8571 (91%) 8566 (91%) –0·01 (–0·85 to 0·82) 1·00 (0·99 to 1·01)
Data are n (%) unless otherwise speciﬁ ed. N=9411 for the simpliﬁ ed package, and 9420 for the full package. †Denominator is 9403 for the simpliﬁ ed package, and 9409 for 
the full package. ‡N=9472 for the full package, and 9459 for the full package. §N=9484 for the simpliﬁ ed package, and 9463 for the full package. ¶N=9483 for the simpliﬁ ed 
package, and 9470 for the full package. ||Denominator is 9391 for the simpliﬁ ed package, and 9378 for the full package. **N=9487 for the simpliﬁ ed package, and 9471 for 
the full package. ††N=9407 for the simpliﬁ ed package, and 9415 for the full package. ‡‡N=9468 for the simpliﬁ ed package, and 9461 for the full package.
Table 4: Sensitivity analysis for the trial outcomes excluding Philippines sites, for the modiﬁ ed intention-to-treat population
See Online for appendix
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sites as suggested by the sensitivity analysis and earlier 
systematic review.5 
Our ﬁ ndings challenge the concept of active manage-
ment of the third stage of labour as a package of inter-
ventions. Eﬀ ective prevention of post-partum haemor rhage 
can be accomplished by an intramuscular injec tion of 
oxytocin 10 IU after delivery of the baby and present 
evidence suggests that the uterotonic compo nent of the 
active management package is the essential component. 
The strengths of our study were its size and the diversity 
of settings of the study sites. We used a secure method of 
allocation concealment that allocated the women only 
after speciﬁ c data were entered. Furthermore, the large 
number of participants allowed us to implement the study 
at a realistic scale in line with the prevalence of severe 
postpartum haemorrhage recorded in other work. The 
data for measured blood loss were collected consistently 
across the trial sites. The adherence to trial intervention 
in terms of cord management was high—in previous 
trials of active versus expectant management, adherence 
with cord management was between 46% and 99%.5 
Because of the nature of the intervention we could not do 
the trial in a double-blind manner. We acknowledged the 
potential for bias and attempted to minimise this risk by 
providing standard training for staﬀ  who were going to 
implement the trial interventions. However, we could not 
make blind outcome assessments. 
Our study is relevant both to health-facility settings and 
to those in which health-care personnel do not have the 
skills to apply controlled cord traction safely. However, 
we could not have done the trial in a non-facility setting 
precisely because such personnel are not available. The 
issue investigated is also relevant to settings in which 
skilled attendants are available but women prefer a 
hands-oﬀ  mode of placental delivery. Our ﬁ ndings 
suggest such placental delivery can be safely oﬀ ered in 
those circumstances.
Recruitment interruptions and the high number of 
deliveries in the Philippines resulted in loss of about 5% 
of forms. However, those losses were similar in both 
groups of the trial. The high rates of ergometrine use in 
one of the Philippine hospitals was another justiﬁ cation 
for the sensitivity analysis, which supported the hypoth-
esis that the overall increase in manual removal could be 
attributable to ergometrine use. However, this analysis 
was post hoc and the increase in manual removal could 
be attributable to other unknown factors.
Our ﬁ ndings have several implications for clinical 
practice. Simpliﬁ cation of the active management of 
third stage of labour is possible: an intramuscular 
injection of oxytocin 10 IU after delivery of the baby 
should be regarded as the primary intervention for 
prevention of haemorrhage. Injections are increasingly 
being used in settings in which skilled birth attendants 
are not available but a trained health worker is present. 
In such settings, oxytocin should be used as the routine 
uterotonic for prevention of post-partum haemorrhage 
even if controlled cord traction cannot be implemented. 
Such a policy could also result in cost savings by 
eliminating the need for training in cord traction skills. 
In settings in which skilled birth attendants are available, 
the full package of oxytocin and controlled cord traction 
should be preferred especially if the shortest possible 
third-stage duration is desirable. Because a few women 
will eventually require controlled cord traction with the 
simpliﬁ ed package and it is the ﬁ rst procedure to be 
attempted in case of retained placenta, we believe that 
teaching of controlled cord traction in medical and 
midwifery curricula should continue.
Our study likewise has implications for future research. 
A substantial proportion of maternal deaths from haem-
or rhage take place in settings in which skilled birth 
attendants and facility-based care are not available. Our 
ﬁ ndings strengthen the need to focus on strategies to 
scale up the use of oxytocin in peripheral health-care 
settings  as the primary component of active management 
of the third stage of labour. In this context, the use of 
task-shifting strategies to expand access should be 
considered and assessed. Such scaling-up eﬀ orts could 
be aided by use of prophylactic oxytocin in a pre-
ﬁ lled, compact, auto-disabled device system. A cluster-
randomised trial to investigate the eﬀ ects of this system 
on post-partum haemorrhage at community level in 
Ghana is under way (NCT01108289). In settings in which 
no injection is possible, the role of misoprostol should be 
assessed with similarly rigorous research.
We were not able to examine any possible role of 
uterine massage in reducing blood loss in this trial. 
Uterine massage remains one component of third-stage 
management that can be implemented without any need 
for technology or skilled birth attendants. However, it has 
Panel: Research in context
Systematic review
We searched PubMed and the Cochrane Library with the 
terms “postpartum hemorrhage” and “randomised 
controlled trial” for trials and systematic reviews assessing 
controlled cord traction. We indentiﬁ ed one review20 at 
protocol stage and one pilot randomised trial,13 which 
included 200 women and suggested a potential protective 
eﬀ ect of controlled cord traction on blood loss. The date of 
the last search was Feb 7, 2012.
Interpretation
Our study provides the largest evidence so far of the eﬀ ect of 
controlled cord traction as part of active management. 
Controlled cord traction adds only marginally to the beneﬁ cial 
eﬀ ect of the full package. Because the main component of 
the management package is oxytocin, in settings in which no 
skilled birth attendants are present to give the full package, 
eﬀ orts should focus on the uterotonic (primarily oxytocin) to 
reduce post-partum haemorrhage.
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not been rigorously assessed so far.21 The variation in use 
of uterine massage across study sites suggests that 
uncertainty remains among practitioners and a thorough 
investigation of the preventive and therapeutic use of this 
intervention would be timely.
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